发明名称 |
THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER |
摘要 |
The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN 18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained. |
申请公布号 |
WO2014146778(A1) |
申请公布日期 |
2014.09.25 |
申请号 |
WO2014EP00719 |
申请日期 |
2014.03.17 |
申请人 |
GANYMED PHARMACEUTICALS AG;TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZGEMEINNÜTZIGE GMBH |
发明人 |
SAHIN, UGUR;TÜRECI, ÖZLEM |
分类号 |
C07K16/28;A61K39/395;A61P35/00;C07K16/30 |
主分类号 |
C07K16/28 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|